Background: Extranodal involvement, including central nervous system (CNS), is a frequent event in patients with mantle cell lymphoma (MCL). However, the incidence, risk factors, and impact on outcome remain controversial.
introduction
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin's lymphoma derived from mature B cells usually coexpressing CD5 and histologically characterized by a nodular or diffuse proliferation of atypical lymphocytes. Two cytological variants of MCL have been identified, classical and blastoid, the latter including pleomorphic and blastic subtypes [1] . MCL is genetically characterized by 11q13 translocations and Bcl-1 rearrangement. This alteration leads to the overexpression of cyclin D1, which plays an important role in the cell cycle control at the G 1 -S transition by overcoming the suppressor effect of retinoblastoma protein and p27 Kip . MCL accounts for 5%-10% of lymphomas and particularly occurs in elderly males who, at diagnosis, frequently show advanced disease, generalized lymphadenopathy, and splenomegaly. The disease has an adverse clinical course characterized by a poor response to chemotherapy and a median overall survival (OS) of 3-5 years [2] [3] [4] [5] [6] .
Extranodal involvement, including bone marrow, gastrointestinal tract, and Waldeyer's ring, is a well-known feature in patients with MCL. The risk for central nervous system (CNS) infiltration was first reported by Bedotto et al. [7] in 1986 and Ellison et al. [8] , and subsequently confirmed by our own group [9] in a series of 22 patients of whom five (22%) eventually had CNS involvement, and by others [10, 11] , who reported an overall incidence of 4% and 9%, respectively. However, the incidence, predicting factors, and outcome of CNS involvement in patients with MCL have not been thoroughly investigated in large series of patients from single institutions.
The aim of the present study was to assess the incidence and factors for CNS involvement in patients with MCL diagnosed and followed up at a single institution. In addition, we analyzed the clinical features, therapy, and outcome of patients with MCL once CNS infiltration was detected. Complete response (CR) was defined as the total disappearance of tumor masses and disease-related symptoms as well as the normalization of the initial abnormal tests for at least 1 month. Partial response (PR) was considered when tumor masses or organ infiltration decreased by at least 50% along with the disappearance of disease-related symptoms. Patients not included in these categories and early deaths were considered as nonresponders. Informed consent to use the clinical data was required from all the patients in accordance with the local Ethic Committee guidelines.
assessment of CNS involvement
The diagnosis of CNS infiltration was based on clinical findings and on the presence of malignant cells in cerebrospinal fluid (CSF), consistent with the diagnosis of MCL. In the first 20 patients of the present series, who have been previously reported [9] , a lumbar puncture was not carried out at diagnosis unless CNS involvement was suspected on clinical grounds. In the subsequent 62 cases, CSF assessment by a lumbar puncture was included as one of the staging maneuvers at diagnosis. Cells from CNS fluid were cytospinned and stained with May-Grünwald-Giemsa for morphology assessment. In some cases, cells from CNS were stained with a panel of monoclonal antibodies that included CD19, CD20, CD23, kappa and lambda light chains, CD3, and CD5. CT or magnetic resonance imaging (MRI) scans of the brain were done to detect parenchymal or meningeal infiltrations when such involvement was suspected.
Data collected at the time of diagnosis of CNS infiltration included neurological symptoms, physical examination findings, diagnostic procedures, stage of the disease, treatment, and response.
statistical methods
Differences among the subgroups of patients were compared with the Fisher's exact test (two-tailed) or the Student's t-test. OS was defined as the time from diagnosis to the time of death or last follow-up. Patients still alive were censored at the last known date of contact. The actuarial survival analysis was carried out according to the method described by Kaplan and Meier [12] and differences in survival analyzed by the log-rank test.
Prognostic factors found to be significant in the univariant analysis were included in a multivariate analysis carried out by the stepwise proportional hazard regression method of Cox. The influence of CNS infiltration on survival was assessed in a time-dependent manner by means of the method described by Mantel and Byar [13] . P values <0.05 were considered statistically significant.
results

patient characteristics
The main initial characteristics of the 82 patients are detailed in Table 1 . Median age was 61 years (range, 40-84 years) and 73% of patients were males. Fifty-nine of 80 patients (74%) were diagnosed with typical morphologic variant and 21 with blastoid morphology (26%), including pleomorphic (five cases) and blastic (16 cases) subtypes. MCL showed a diffuse growth pattern in 71 cases, nodular in eight, and mantle zone in one case. In two patients with lymph node biopsy-based diagnosis of MCL, the histologic subtype could not be established. Immunohistochemical staining for Ki-67 was available in 46 patients, in 18 of them (39%) being ‡50%. The vast majority of patients presented with advanced disease (92% in stage III-IV). Extranodal involvement was found in 74 patients (90%), including bone marrow infiltration in 64 of 79 patients (81%). The median leukocyte and lymphocyte counts were 8.8 · 10 9 /l (1.1-322 · 10 9 /l) and 2.75 · 10 9 /l (0.50-99 · 10 9 /l), respectively. A lymphocyte count ‡5 · 10 9 /l was observed in 29 cases. Fourteen patients presented with hemoglobin <100 g/l and the platelet count was <100 · 10 9 /l in 18 patients. As per the IPI, 16% patients were of low risk, [14] , whereas 11 additional patients were treated with this regimen in subsequent recurrences. One patient was not treated because she died before starting therapy. Seventy-nine patients were assessable for response. CR, PR, and failure rates were 17%, 49%, and 34%, respectively. At the time of the last follow-up, 63 patients (77%) had died, with a median OS of 28 months (range, 1-136).
CNS involvement
Eleven of 84 patients (13%) developed CNS involvement. In one asymptomatic patient, CSF infiltration was detected in the lumbar puncture carried out during staging maneuvers. This patient was diagnosed with typical diffuse MCL in a lymph node biopsy. She presented with advanced disease (stage IV), increased serum LDH and b 2 -microglobulin levels, and a high-risk IPI. The risk of CNS involvement at diagnosis as assessed by systematic lumbar puncture was of 1/62 [1.6%; 95% confidence interval (CI) 0% to 9%].
The remaining 10 patients eventually developed CNS involvement during the course of the disease. Main characteristics of these patients are listed in Table 2 . Histology of lymph node biopsies disclosed a typical subtype in six cases (one nodular, five diffuse) and blastoid morphology in five (four blastic, one pleomorphic). All patients had advancedstage disease, nine patients (82%) presented with bone marrow infiltration, and eight cases (73%) presented with ‡2 extranodal sites involved. Four patients (36%) had B symptoms and a poor performance status. As per the IPI, four patients (36%)
were of low-intermediate risk, three (28%) of highintermediate risk, and four (36%) of high risk. Two of eleven patients (18%) had achieved a CR with first-line combination chemotherapy and a PR was observed in four cases (36%).
Development of CNS infiltration was seen at a median time of 25 months from diagnosis (range, 5-130). All 10 patients who developed CNS infiltration during follow-up presented with neurological symptoms: facial palsy in four cases, sciatalgia in four, diplopia in two, paraparesis in two, and confusional syndrome, trigeminal sensitive symptoms, and upper or lower limbs paresthesias or dysesthesias in one patient each. In two patients (patient 6 and patient 9) the lumbar puncture was not carried out because of their critical status. All except one patient displayed atypical lymphocytes in the CSF, consistent with the diagnosis of MCL. The latter patient (patient 7) was diagnosed with CNS involvement based on the clinical symptoms that improved after intrathecal therapy. In two patients, the flow cytometry analysis of CSF showed a characteristic MCL population (monoclonal B cells CD5 positive, CD23 negative, strong CD20, with relatively intense surface restricted light chain expression). CT or MRI scans were carried out in three patients with negative results in all cases. Three of the 10 patients who developed CNS infiltration during the course of the disease had received chemotherapy containing high-dose MTX (first-line in two cases; salvage therapy in one). At the time of CNS infiltration, five patients were under treatment and the remaining five patients had progressive disease.
risk and factors predicting CNS involvement
The risk of CNS involvement at 5 years was 26% (0.95 CI 10% to 42%) (Figure 1 ). CNS infiltration was more frequently observed in patients with blastoid histology (P = 0.005) (Figure 2A ), Ki-67 expression ‡50% (P = 0.017) ( Figure 2B) , high LDH serum level (P = 0.006) ( Figure 2C ) or intermediateand high-risk IPI (P = 0.05) ( Figure 2D ). Extranodal 
treatment and outcome of the patients
The most relevant features of patients developing CNS involvement are summarized in Table 3 . All but two patients (patient 6 and patient 9) were treated with intrathecal chemotherapy (MTX 10 mg, hydrocortisone 20 mg, cytarabine 30 mg). In addition, seven patients (patients 1-5, 7, and 11) received combination chemotherapy that included high-dose MTX in four cases (patients 1, 2, 5, and 7). All the patients with CNS infiltration died, with a median survival from the time of CNS involvement of 3 months To analyze the impact of CNS infiltration on OS, we first carried out a raw comparison between the median OS of patients with and without CNS involvement (24 versus 29 months, respectively; P > 0.1, NS). Subsequently, CNS infiltration was analyzed as a time-dependent variable; patients developing CNS involvement showed a significantly poorer OS (P < 0.001; RR: 4.7).
discussion
The reported incidence of CNS involvement in patients with lymphoma varies from 2% to 27% in different series [15] [16] [17] [18] [19] [20] [21] [22] . This wide variation is most likely explained by patients' inclusion criteria, different histologic subtypes, and methods to assess CNS infiltration [23] . In some aggressive lymphomas, such as lymphoblastic lymphoma or Burkitt's lymphoma, CNS infiltration is a well-known feature in the natural history of the disease, whereas, on the contrary, CNS infiltration is virtually absent in indolent lymphomas and, if present, it is usually related to histologic transformation [24, 25] . The incidence in different studies of CNS involvement in patients with MCL is also highly variable, ranging from 4% to 22%. The first reports describing this complication were published two decades ago [7, 8] . Subsequently, other series describing the presenting and evolutive features of patients with MCL were reported but in all these studies little attention was paid to CNS disease, this being considered an infrequent event with an incidence inferior to 10%. As a result, CNS assessment has not been part of the routine initial work-up in patients with MCL. In the present series, CNS involvement was found in one of 62 asymptomatic patients at diagnosis (1.6%). In all, 11 of 82 patients developed CNS infiltration during their clinical course, with an actuarial risk at 5 years of 26%. Discrepancies between our series and others are not easy to explain, but they could be due in part to differences in the duration of the follow-up. Risk factors for a higher probability of CNS involvement were blastic subtype, high Ki-67 immunostaining, high serum LDH levels, and high-risk IPI. Of note, most of these variables are in fact related to the proliferation of the disease.
The most frequent clinical manifestations of CNS involvement included signs and symptoms related to high intracranial pressure or meningeal infiltration, and mainly consisted in mental status changes, headache, and cranial nerve palsies. Nevertheless, signs and symptoms of CNS involvement may be very subtle, warranting a high degree of suspicion of CNS infiltration.
The mechanisms by which MCL involves the CNS are not completely understood. The possibility of histological transformation into a more aggressive lymphoma type or of progression from typical to blastoid histology cannot be completely ruled out. However, none of our six patients diagnosed with typical MCL presented with signs to suspect such an event and, in addition, three of them showed lymphoid cells of typical MCL in the CSF. On the other hand, it is well known that cellular adhesion molecules (CAM) are involved in the pattern of growth and dissemination of lymphoproliferative disorders [26] [27] [28] [29] [30] . MCL is characterized by low levels or absence of L-selectin and CD11c, low expression of CD11a/CD18 (Leukocyte function antigen (LFA)-1), and high levels of CD44, CD54 (Intracellular adhesion molecule-1), and VLA-5 [31, 32] . In this regard, the lack of expression of LFA-1 has been related to lymphoma dissemination and aggressive behavior [30, 33] . Moreover, the strong expression of VLA-5 has been associated with extranodal involvement [30] . However, no correlation between the pattern of CAM and CNS involvement has been found yet in MCL [9] . In MCL, CNS involvement is usually a late event (median time from diagnosis of 25 months in the present series). Due to this fact, CNS infiltration could be overlooked in studies with short follow-up. The relatively high risk of CNS infiltration in MCL leads to the question of whether or not treatment strategies in this type of lymphoma should take into consideration such a complication. In this regard, CNS prophylaxis is recommended in patients with lymphoma and a high risk for this complication, although its usefulness has not been completely demonstrated [16] . The situation in MCL is even further complicated because of a number of factors. First, CNS infiltration is a late event in the course of the disease that is usually found in the context of relapsing or refractory disease. Secondly, the incidence of CNS infiltration observed in this series in patients receiving high-dose MTX-containing regimens was exactly the same than that detected in the remaining patients. Thirdly, the cause of death was systemic progression of the disease in all cases. What is necessary, therefore, are more effective treatments to control the disease as a whole and to prevent relapse. In practical terms, the present results support to carry out CNS prophylaxis only in those patients of high risk, namely those with blastoid MCL or high LDH serum levels. In fact, this is the current policy in our department.
In conclusion, CNS involvement is a frequent complication in patients with MCL. Blastoid histology, high proliferative index measured by Ki-67 immunostaining, high serum LDH or intermediate and high-risk IPI are associated with a higher risk to develop this complication. The fact that in most cases CNS involvement occurs late in the course of the disease as part of a generalized clinical relapse or progression indicates that better therapies for MCL are urgently needed. Whether there is a role for CNS prophylaxis in patients with MCL should be investigated as part of potentially more effective treatments for this type of lymphoma. 
